Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib + capecitabine in anthracycline/taxane-failed metastatic triple-negative breast cancer
CTR20220336Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chiauranib in triple-negative breast cancer (TNBC), sponsored by Akeso, Inc. Primary endpoint: Objective response rate (ORR). Started Feb 2022; status: terminated.
02
Drugs
chiauranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20220336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220336.